Design, Synthesis, Characterization, and Antitumor Activities of Benzimidazole-functionalized Organoruthenium Complexes Bearing Fluorine Group

Basit Öğe Kaydı
dc.contributor.authorPasahan, Ramazan
dc.contributor.authorDemirci, Ozlem
dc.contributor.authorTaskin, Irmak Icen
dc.contributor.authorPasahan, Aziz
dc.contributor.authorSever, Meryem Ruveyda
dc.contributor.authorGok, Yetkin
dc.contributor.authorAktas, Aydin
dc.date.accessioned2026-04-04T13:32:56Z
dc.date.available2026-04-04T13:32:56Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground This work presents the synthesis of Ru(II)NHC complexes bearing a series of 4-fluorobenzyl group. These complexes have been characterized by a variety of spectroscopic methods (1H NMR, 13C NMR, and FTIR) and by elemental analysis techniques.Methods These complexes' antitumor activities against SH-SY5Y (human neuroblastoma) and HCT116 (human colon cancer) were investigated by 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT) assay.Results The results showed that all the synthesized complexes exhibited significant cytotoxic effect with low IC50 values 15 +/- 0.57, 15.26 +/- 0.71, 7.64 +/- 0.30, 27.66 +/- 0.36 and 14.45 +/- 0.84 (mu g/mL) respectively.Conclusion Furthermore, apoptosis assessed by double labeling with Annexin V-FITC/PI indicated that complexes 1b and 1d can effectively induce apoptosis and inhibit cell proliferation at the S phase in SH-SY5Y cells. Taken together, Ru(II)NHC complexes containing the 4-fluorobenzyl group have significant potential for the development of novel, highly effective anticancer agents.
dc.description.sponsorshipInonu University Research Fund [IUBAP TOA-2022-2908]
dc.description.sponsorshipThis work was financially supported by Inonu University Research Fund (IUBAP TOA-2022-2908).
dc.identifier.doi10.2174/0115734064331622241113032042
dc.identifier.endpage553
dc.identifier.issn1573-4064
dc.identifier.issn1875-6638
dc.identifier.issue6
dc.identifier.orcid0000-0001-8496-6782
dc.identifier.orcid0000-0002-0657-3884
dc.identifier.orcid0000-0002-3221-1422
dc.identifier.orcid0000-0001-9271-1528
dc.identifier.pmid39950455
dc.identifier.scopus2-s2.0-105013020916
dc.identifier.scopusqualityQ3
dc.identifier.startpage546
dc.identifier.urihttps://doi.org/10.2174/0115734064331622241113032042
dc.identifier.urihttps://hdl.handle.net/11616/108804
dc.identifier.volume21
dc.identifier.wosWOS:001548464300010
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofMedicinal Chemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectAntitumor activity
dc.subjectbenzimidazole
dc.subjectDNA binding
dc.subjectN-heterocyclic carbenes
dc.subjectorganometallic
dc.subjectruthenium
dc.titleDesign, Synthesis, Characterization, and Antitumor Activities of Benzimidazole-functionalized Organoruthenium Complexes Bearing Fluorine Group
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu